Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.
Partnership with The Chase Group Results in Successful Placement for Eisai Global Oncology Business Unit
The Chase Group is proud to partner with Eisai and support their human health care mission by securing a strong and agile leader for their…
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program…
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… -
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…